<DOC>
	<DOCNO>NCT00374166</DOCNO>
	<brief_summary>The objective evaluate efficacy safety two dos SSR149415 ( 250 mg 100 mg twice daily ) compare placebo paroxetine 20 mg daily outpatient generalize anxiety disorder</brief_summary>
	<brief_title>An Eight-week Study Evaluating Efficacy Tolerability Two Doses SSR149415 Outpatients With Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Diagnosis generalize anxiety disorder , define Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) criterion confirm semistructured Mini International Neuropsychiatric Interview ( MINI ) General Anxiety Disorder ( GAD ) Plus Module . Total score less 22 ( Hamilton Anxiety rating scale ) HAMA . MontgomeryAsberg Depression Rating Scale ( MADRS ) total score great 17 . Patients current history ( within 6 month ) major depressive disorder history presence bipolar disorder psychotic disorder . Patients alcohol dependence abuse substance dependence abuse past 12 month except nicotine caffeine dependence . Patients use follow prior entry Acute Phase : antipsychotic within 3 month , antidepressant include Monoamine oxidase inhibitor ( MAOIs ) within 1 month , anxiolytic within 2 week , moodstabilizer ( lithium , anticonvulsant ) within 1 month , and/or high dose prolong benzodiazepine ( continuous use 3 month prior admission ) use . The investigator evaluate whether reason patient may participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Anti-anxiety agent</keyword>
	<keyword>antidepressive agent</keyword>
	<keyword>control clinical trial</keyword>
</DOC>